October 21, 2019 06:45 AM EDTUpdated 12:52 PM
R&D

Clay Sie­gall’s $614M wa­ger on tu­ca­tinib pays off with solid­ly pos­i­tive piv­otal da­ta and a date with the FDA

John Carroll

Editor & Founder

Back at the be­gin­ning of 2018, Clay Sie­gall snagged a can­cer drug called tu­ca­tinib with a $614 mil­lion cash deal to buy

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Merus’ Phase 2 over­all sur­vival da­ta reach ‘home run’ sce­nario — an­a­lyst

The ‘MA­HA re­port’: Four key take­aways on vac­cines, med­i­cine and the phar­ma in­dus­try

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

Volas­tra un­veils first hu­man da­ta of its sol­id tu­mor drug tar­get

Ge­of­frey Porges ex­its Schrödinger with CFO swap; A new board seat for As­traZeneca's Pas­cal So­ri­ot

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times